WO2012135397A3 - Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome - Google Patents

Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome Download PDF

Info

Publication number
WO2012135397A3
WO2012135397A3 PCT/US2012/031047 US2012031047W WO2012135397A3 WO 2012135397 A3 WO2012135397 A3 WO 2012135397A3 US 2012031047 W US2012031047 W US 2012031047W WO 2012135397 A3 WO2012135397 A3 WO 2012135397A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer cell
cell line
level
gene expression
expression pattern
Prior art date
Application number
PCT/US2012/031047
Other languages
French (fr)
Other versions
WO2012135397A2 (en
Inventor
Michael P. Lisanti
Federica Sotgia
Original Assignee
Lisanti Michael P
Federica Sotgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lisanti Michael P, Federica Sotgia filed Critical Lisanti Michael P
Publication of WO2012135397A2 publication Critical patent/WO2012135397A2/en
Publication of WO2012135397A3 publication Critical patent/WO2012135397A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)

Abstract

A method for discovering a biological marker (biomarker) of any cancer whose growth may be modulated by mitochondrial oxidative metabolism is disclosed. The method comprises (a) contacting a set of at least one or more metabolites (e.g., 3-hydroxybutyrate or lactate or acetoacetate or oxaloacetate or citrate or a-ketoglutarate or glutamine or combinations thereof) to a first sample of a cancer cell line, a test cancer cell line; (b) assessing a level of gene expression pattern in the test cancer cell line; and (c) comparing the level of gene expression pattern of the test cancer cell line with a level of gene expression pattern in a control cancer cell line, whereby a difference between the level of the gene expression pattern in the test cancer cell line and the level of gene expression pattern in the control cancer cell line is a biomarker indicating mitochondrial oxidative metabolism in the cancer represented by the cancer cell.
PCT/US2012/031047 2011-03-29 2012-03-29 Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome WO2012135397A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161468700P 2011-03-29 2011-03-29
US201161468710P 2011-03-29 2011-03-29
US61/468,710 2011-03-29
US61/468,700 2011-03-29

Publications (2)

Publication Number Publication Date
WO2012135397A2 WO2012135397A2 (en) 2012-10-04
WO2012135397A3 true WO2012135397A3 (en) 2012-12-06

Family

ID=46932329

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/031047 WO2012135397A2 (en) 2011-03-29 2012-03-29 Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome

Country Status (1)

Country Link
WO (1) WO2012135397A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201408651TA (en) 2012-06-27 2015-01-29 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US20170307615A1 (en) * 2014-09-24 2017-10-26 Geisinger Health System Immunohistochemistry Quality Management Program Using Cultured Cell Lines for Tissue Microarray (TMA) Blocks
EP4242329A3 (en) 2014-12-08 2023-10-25 Berg LLC Use of markers including filamin a in the diagnosis and treatment of prostate cancer
ES2954456T3 (en) 2015-03-25 2023-11-22 Massachusetts Gen Hospital Digital analysis of circulating tumor cells in blood samples
JP6895971B2 (en) * 2015-09-10 2021-06-30 クラウン バイオサイエンス，インコーポレイテッド（タイツァン） Histological diagnosis and treatment of the disease
US11371101B2 (en) * 2016-10-27 2022-06-28 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
WO2018177326A1 (en) * 2017-03-29 2018-10-04 Crown Bioscience Inc. (Taicang) System and method for determining karenitecin sensitivity on cancer
CN110618271B (en) * 2019-09-29 2023-06-13 中国医学科学院肿瘤医院 Prognosis prediction method for non-small cell lung cancer
EP4253567A1 (en) 2022-03-31 2023-10-04 OncoAssure Limited A method of predicting risk of an aggressive or recurrent cancer
CN115637253B (en) * 2022-11-30 2023-04-07 北京大学口腔医学院 Immune extract and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045463A1 (en) * 2004-10-25 2008-02-21 Ajay Verma Methods For Lowering Hif-1 Mediated Gene Expression
WO2010096574A1 (en) * 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080045463A1 (en) * 2004-10-25 2008-02-21 Ajay Verma Methods For Lowering Hif-1 Mediated Gene Expression
WO2010096574A1 (en) * 2009-02-20 2010-08-26 Lisanti Michael P A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm

Also Published As

Publication number Publication date
WO2012135397A2 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
WO2012135397A3 (en) Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
BR112013003391B8 (en) METHOD TO DIAGNOSE PANCREATIC CANCER IN AN INDIVIDUAL
WO2012015765A3 (en) Method for using gene expression to determine prognosis of prostate cancer
IN2014KN02647A (en)
EP3511717A3 (en) Biodosimetry panels and methods
WO2010104345A2 (en) Apparatus for integrated real-time nucleic acid analysis, and method for detecting a target nucleic acid using same
NZ614566A (en) Methods and systems for assessing clinical outcomes
WO2012004790A3 (en) Nucleic acid aptamer-based detection methods characterized by signal enhancement
NZ628281A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
WO2012143562A3 (en) Analyzing the expression of biomarkers in cells with clusters
GB201017326D0 (en) Method for in vitro detection and differentiation of pathophysiological states
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
BRPI1013896A2 (en) Yeast cell, and methods for producing an isoprenoid compound and for detecting in a biological sample the presence or absence of a genetically microbial cell.
WO2014140974A3 (en) System and method for determining risk of diabetes based on biochemical marker analysis
EP2619587A4 (en) Biomarkers for recurrence prediction of colorectal cancer
WO2009149319A3 (en) Gene expression profiles associated with asthma exacerbation attacks
EP2328105A3 (en) Method for determining the presence of disease
BR112013004044A2 (en) compositions and methods for quantifying a nucleic acid sequence in a sample.
WO2013006278A3 (en) Identity elucidation of unknown metabolites
WO2013055651A3 (en) Precision phenotyping using score space proximity analysis
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2015006657A3 (en) Method for the diagnosis and prognosis of cancer
WO2011132989A3 (en) Methylation marker for diagnosis of cervical cancer
WO2014146035A3 (en) Compositions and methods for cancer diagnosis
NZ594086A (en) A drug identification protocol for type 2 diabetes based on gene expression signatures

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12764261

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12764261

Country of ref document: EP

Kind code of ref document: A2